Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282874 | 0.91 | AOC3 (0.31) | AOC3 | |
| SCHEMBL1282854 | 0.90 | RET (0.33) | RETALDH1A1MAPK1AOC3PIK3R1 | |
| SCHEMBL1282608 | 0.89 | PIK3R1 (0.32) | ALDH1A1MAPK1AOC3PIK3R1PIK3CA | |
| SCHEMBL1282961 | 0.83 | AOC3 (0.31) | AOC3PIK3R1PIK3CA | |
| SCHEMBL1282073 | 0.82 | AOC3 (0.31) | AOC3 | |
| SCHEMBL1283101 | 0.81 | — | — | |
| SCHEMBL1283245 | 0.81 | RET (0.34) | RETAOC3PIK3R1PIK3CA | |
| SCHEMBL1283035 | 0.80 | ABL1 (0.37) | PIK3CA | |
| SCHEMBL1283624 | 0.80 | ALDH1A1 (0.40) | ALDH1A1MAPK1MEN1KMT2AOPRM1 | |
| SCHEMBL1283192 | 0.80 | F10 (0.30) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | RET 4501/4885ALDH1A1 2614/4885MAPK1 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.